Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
April 16, 2024 08:30 ET
|
Palisade Bio, Inc.
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)...
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
April 10, 2024 08:15 ET
|
Palisade Bio, Inc.
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 (GLOBE...
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
February 15, 2024 08:35 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Palisade Bio Provides Corporate Update and Reiterates Guidance
February 13, 2024 08:35 ET
|
Palisade Bio, Inc.
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe...
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
November 10, 2023 08:05 ET
|
Palisade Bio, Inc.
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment...